CONCORD BIOTECH Latest Share Price (CONCORDBIO)
TODAY IN ONE LINE
CONCORDBIO jumped 3.6% on average volume, outperforming Nifty's -0.3% move, with no exchange filing today, suggesting a market-driven move.
With a market cap of ₹15,797.05 Cr., it trades at a P/E of 57.37. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
CONCORD BIOTECH flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Healthy Operating MarginsOPM is structurally strong at 33.3%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 37.0% YoY
- ●Expensive ValuationTrading at a high P/E ratio of 51.6x
- ●Rising Receivables vs SalesReceivables grew 44.5% outpacing sales growth of 18.0%
Latest CONCORD BIOTECH News
What changed recently?
Recent events, corporate actions, and announcements.
CONCORD BIOTECH valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for CONCORD BIOTECH, framed against the sector median so the premium or discount is obvious at a glance.
CONCORD BIOTECH trades at a P/E of 57.37× and P/B of 7.83×, against the Healthcare sector median P/E of 46.02×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
CONCORD BIOTECH technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for CONCORD BIOTECH — derived from the latest tape, not yesterday's close.
CONCORD BIOTECH last traded at ₹1,505.7 with an intraday range of ₹1,426.9–₹1,529 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹1505.70| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1751.70 | +246.00 | +16.34% |
| R3 | 1649.60 | +143.90 | +9.56% |
| R2 | 1589.30 | +83.60 | +5.55% |
| R1 | 1547.50 | +41.80 | +2.78% |
| PIVOT | 1487.20 | -18.50 | -1.23% |
| CURRENT | 1505.70 | — | — |
| S1 | 1445.40 | -60.30 | -4.00% |
| S2 | 1385.10 | -120.60 | -8.01% |
| S3 | 1343.30 | -162.40 | -10.79% |
| S4 | 1241.20 | -264.50 | -17.57% |
CONCORDBIO is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹1426.9–₹1450.6
Trading Above opening range, showing Bullishness
CONCORD BIOTECH financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for CONCORD BIOTECH — consolidated or standalone — with margins, YoY growth and key ratios inline.
CONCORD BIOTECH reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹15,797.05 Cr. and reported EPS of ₹5.85.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 1,200 | 1,055 ▼ 12.1% |
| Sales Growth YoY %Derived | 18.01% | -12.10% |
| Other Income | 44 | 52 ▲ 17.8% |
| Total Income | 1,245 | 1,107 ▼ 11.0% |
| 306 | 246 ▼ 19.6% | |
| Gross ProfitDerived | 895 | 809 ▼ 9.5% |
| Gross Margin %Derived | 74.54% | 76.71% |
| 388 | 442 ▲ 13.8% | |
| EBITDA (Operating Profit)Derived | 506 | 367 ▼ 27.4% |
| OPM %Derived | 42.19% | 34.83% |
| 55 | 71 ▲ 30.2% | |
| Profit Before Tax (PBT) | 496 | 342 ▼ 31.1% |
| 123 | 85 ▼ 30.5% | |
| Effective Tax %Derived | 24.79% | 25.00% |
| Total Profit for Period | 372 | 259 ▼ 30.2% |
| Less: Non-controlling Interests | — | -2 |
| Net Profit (Owner's PAT)Derived | 372 | 261 ▼ 29.8% |
| Net Profit Margin %Derived | 30.97% | 24.73% |
| PAT Growth YoY %Derived | 20.62% | -29.80% |
| Earnings Per Share (EPS ₹) | 35.52 | 24.94 ▼ 29.8% |
| Diluted Shares Outstanding (Cr) | 10 | 10 ▲ 0.0% |
| Share of Profit from Associates/JVs | -1 | 3 ▲ 320.0% |
| Other Comprehensive Income (Net of Tax) | 6 | 55 ▲ 825.5% |
| Total Expenses (incl. D&A & Interest) | 749 | 766 ▲ 2.3% |
| Material Cost % of RevenueDerived | 22.02% | 24.11% |
| Employee Cost % of RevenueDerived | 11.58% | 16.77% |
| Other Cost % of RevenueDerived | 20.77% | 25.11% |
| Interest Coverage (x)Derived | 853.88x | 1,034.40x |
| Period | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|
| Revenue from Operations | 1,017 | 1,200 ▲ 18.0% | 1,055 ▼ 12.1% | |
| Sales Growth YoY %Derived | — | 18.01% | -12.10% | |
| Other Income | 34 | 44 ▲ 31.6% | 52 ▲ 17.8% | |
| Total Income | 1,051 | 1,245 ▲ 18.4% | 1,107 ▼ 11.0% | |
229 | 306 ▲ 33.3% | 246 ▼ 19.6% | ||
| Gross ProfitDerived | 788 | 895 ▲ 13.6% | 809 ▼ 9.5% | |
| Gross Margin %Derived | 77.46% | 74.54% | 76.71% | |
356 | 388 ▲ 9.0% | 442 ▲ 13.8% | ||
| EBITDA (Operating Profit)Derived | 432 | 506 ▲ 17.3% | 367 ▼ 27.4% | |
| OPM %Derived | 42.44% | 42.19% | 34.83% | |
56 | 55 ▼ 2.2% | 71 ▲ 30.2% | ||
| Profit Before Tax (PBT) | 409 | 496 ▲ 21.2% | 342 ▼ 31.1% | |
104 | 123 ▲ 17.7% | 85 ▼ 30.5% | ||
| Effective Tax %Derived | 25.53% | 24.79% | 25.00% | |
| Total Profit for Period | 308 | 372 ▲ 20.6% | 259 ▼ 30.2% | |
| Less: Non-controlling Interests | — | — | -2 | |
| Net Profit (Owner's PAT)Derived | 308 | 372 ▲ 20.6% | 261 ▼ 29.8% | |
| Net Profit Margin %Derived | 30.30% | 30.97% | 24.73% | |
| PAT Growth YoY %Derived | — | 20.62% | -29.80% | |
| Earnings Per Share (EPS ₹) | 29.45 | 35.52 ▲ 20.6% | 24.94 ▼ 29.8% | |
| Diluted Shares Outstanding (Cr) | 10 | 10 ▲ 0.0% | 10 ▲ 0.0% | |
| Share of Profit from Associates/JVs | 3 | -1 ▼ 139.2% | 3 ▲ 320.0% | |
| Other Comprehensive Income (Net of Tax) | -0 | 6 ▲ 81865.8% | 55 ▲ 825.5% | |
| Total Expenses (incl. D&A & Interest) | 642 | 749 ▲ 16.7% | 766 ▲ 2.3% | |
| Material Cost % of RevenueDerived | 18.15% | 22.02% | 24.11% | |
| Employee Cost % of RevenueDerived | 12.10% | 11.58% | 16.77% | |
| Other Cost % of RevenueDerived | 22.93% | 20.77% | 25.11% | |
| Interest Coverage (x)Derived | 148.11x | 853.88x | 1,034.40x |
CONCORD BIOTECH segment analysis : revenue and profit mix.
Disclosed business segments at CONCORD BIOTECH with their share of revenue and profit, switchable between consolidated and standalone reporting.
CONCORD BIOTECH discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for CONCORD BIOTECH.
Our AI distills the core fundamental drivers supporting CONCORD BIOTECH, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
CONCORD BIOTECH's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Operating margin 27.77% significantly exceeds peer median 22.70%, demonstrating superior fermentation-API pricing power.
ROCE 18.20% surpasses peer median, indicating highly efficient capital deployment in specialized fermentation expertise.
Debt-to-equity 0.00x with zero long-term borrowings provides substantial financial flexibility and balance sheet stability.
Operating cash flow ₹151.08 Cr sustains liquidity and supports consistent dividend payments reliably.
Promoter holding 44.08% ensures stable governance and long-term strategic alignment with shareholders.
Key Risks.
Latest quarterly EPS declined 36.8% YoY, signaling significant earnings deterioration and profitability concerns.
TTM revenue declined 24.1% YoY, indicating substantial sales contraction and challenging market headwinds.
P/E ratio 51.64x far exceeds peer median 28.2x, suggesting premium valuation with downside risk.
Quarterly PAT fell 36.80% YoY, raising near-term profitability sustainability and growth trajectory concerns.
Dividend yield 0.53% lags sector average, limiting income appeal for yield-focused investors.
Flip Conditions.
Valuation risk. a P/E above 75 (~1.6× the sector multiple of 46.0) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.25%.
CONCORD BIOTECH peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — CONCORD BIOTECH is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
CONCORD BIOTECH chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for CONCORD BIOTECH — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
CONCORD BIOTECH delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for CONCORD BIOTECH over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in CONCORD BIOTECH stood at 45.0% of traded volume, against a 20-day average of 46.1%.
CONCORD BIOTECH announcements: results, concalls, ratings, M&A.
Filings CONCORD BIOTECH sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
CONCORD BIOTECH files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 124 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Concord Biotech Limited has informed the Exchange about Schedule of meet
Analysts/Institutional Investor Meet/Con. Call Updates
Concord Biotech Limited has informed the Exchange about Transcript
Analysts/Institutional Investor Meet/Con. Call Updates
Concord Biotech Limited has informed the Exchange about Link of Recording
Analysts/Institutional Investor Meet/Con. Call Updates
Concord Biotech Limited has informed the Exchange about Presentation
Shareholders meeting
Concord Biotech Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on July 31, 2026. Further, the company…
Investor decks & rating reports.
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
Investor Presentation
Investor Presentation
CONCORD BIOTECH dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue CONCORD BIOTECH has declared, sequenced by announce and record date.
CONCORD BIOTECH corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About CONCORD BIOTECH: business, sector, key facts.
What CONCORD BIOTECH does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
CONCORD BIOTECH operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: CONCORDBIO, BSE: 543960.
Concord Biotech Limited is an Indian biopharmaceutical company specializing in the research, development, manufacturing, and sale of pharmaceutical products both domestically and internationally. Their core competency lies in fermentation-based Active Pharmaceutical Ingredients (APIs), which are essential components in various medications.
The company's product portfolio is diverse and spans several therapeutic areas. In immunosuppressants, they offer a range of key APIs including tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus. Their oncology segment features APIs such as temsirolimus, everolimus, romidepsin, and several others used in cancer treatments. Concord Biotech also manufactures APIs for antibacterial applications, including mupirocin, polymyxin B sulfate, and fidaxomicin, and for antifungal treatments, offering anidulafungin, caspofungi, and more.
Beyond their own branded APIs, Concord Biotech provides contract research and manufacturing services (CRAMS) focused on fermentation and semi-synthesis products. This business model allows them to leverage their expertise in fermentation processes to offer services to other pharmaceutical companies, contributing to their revenue streams and expanding their reach within the industry.
Established in 1984 and headquartered in Ahmedabad, India, Concord Biotech has a long history in the pharmaceutical sector. Their focus on fermentation-based APIs, combined with their CRAMS services, positions them as a significant player in the global biopharmaceutical market, catering to a wide range of therapeutic needs and client demands. The company's continued success relies on their ability to innovate, maintain high manufacturing standards, and effectively navigate the complexities of the global pharmaceutical landscape.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- Other overvalued NSE stocksScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about CONCORD BIOTECH (CONCORDBIO).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of CONCORD BIOTECH (CONCORDBIO)?
The current share price of CONCORD BIOTECH (CONCORDBIO) is ₹1,505.70. Today, the stock has gained by ₹52.90 (3.64%), trading in a range of ₹1,426.90 to ₹1,529.00. The stock opened at ₹1,439.60 with a trading volume of 3,72,504 shares.
02Is CONCORD BIOTECH stock a good investment for long-term?
CONCORD BIOTECH can be considered for long-term investment based on several factors. The company has a market capitalization of ₹15,797.05 Cr., P/E ratio of 57.37, ROE of 13.03%, and ROCE of 13.09%. The dividend yield stands at 0.5%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of CONCORD BIOTECH stock?
The 52-week high price of CONCORD BIOTECH (CONCORDBIO) is ₹1,704.00, while the 52-week low is ₹987.00. Currently trading at ₹1,505.70, the stock is 52.55% above its 52-week low and 11.64% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy CONCORD BIOTECH stock at the current price?
Whether to buy CONCORD BIOTECH stock at ₹1,505.70 depends on multiple factors. The stock is currently trading with a P/E ratio of 57.37 and P/B ratio of 7.83. Today's performance shows a gain of 3.64%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of CONCORD BIOTECH and when is the next dividend?
CONCORD BIOTECH offers a dividend yield of 0.5%, which means for every ₹100 invested at the current price of ₹1,505.70, you can expect to receive approximately ₹0.50 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of CONCORD BIOTECH?
CONCORD BIOTECH's key financial metrics include: P/E Ratio: 57.37, P/B Ratio: 7.83, ROE: 13.03%, ROCE: 13.09%, Dividend Yield: 0.5%, EPS: ₹5.85, Book Value: ₹192.62, and Debt-to-Equity: 0. The company's market cap stands at ₹15,797.05 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is CONCORD BIOTECH stock performing today in the market?
CONCORD BIOTECH stock opened at ₹1,439.60 and is currently trading at ₹1,505.70, showing a gain of ₹52.90 (3.64%). The intraday high is ₹1,529.00 and low is ₹1,426.90. The trading volume stands at 3,72,504 shares, indicating moderate market participation today.
08What is the P/E ratio of CONCORD BIOTECH and what does it indicate?
CONCORD BIOTECH has a Price-to-Earnings (P/E) ratio of 57.37, which means investors are willing to pay 57.37 for every ₹1 of earnings. With an EPS of ₹5.85, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about CONCORD BIOTECH (CONCORDBIO) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.